Our results showed that CHD5 expression was positively correlated with the stromal scores in 18 types of cancers, was correlated with the immune scores in 19 types of cancers, and was especially significantly negatively correlated with the immune scores in Glioma. Here, CHD5 is linked to central nervous system cancer.